Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEV vaccine effectiveness in pregnant women in Bangladesh
NCT02759991Phase 4Completed
- Sponsor
- Norwegian Institute of Public Health
- Start
- Oct 2017
- Primary completion
- Sep 2019
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of HEV 239 in hepatitis E (HEV) (2 arms), sponsored by Norwegian Institute of Public Health. Primary endpoint: Effectiveness of HEV vaccine in preventing HEV diseases among women in Bangladesh at 2 years. Started Oct 2017; status: completed.
02
Drugs
HEV 239
03
Conditions
hepatitis E (HEV)
Beyond the preview
Go deeper on NCT02759991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02759991.